Jin, 202060First Affiliated Hospital of College of Medicine, Zhejiang University (Hangzhou)ZhejiangDates: 1/17/2020-02/08/2020Last follow-up: 02/08/2020 n = 651Survival: 0.2% death, NR for the othersInclusion: Inpatients with COVID-19.Age: m 45 ± 14.4 ySex: 49.2% femalesGI/liver comorbidities: NRDisease severity: Severe/critical 9.8% Diarrhea: 8.6% (56)Present on admission and prior to treatment.Defined as loose stool >3 times daily. Stool cultures were performed with negative results for all patients. Clostridium difficile not detected in stool and no recent antibiotic use.Median duration was 4 d (IQR, 3–6 d, range, 1–9 d). Most was self-limiting.Nausea/vomiting: 4.3% (28)Present on admission.11 only vomiting; 10 only nausea; 3 nausea, vomiting and diarrhea; 4 nausea and vomiting.Any GI Symptom: 11.4 (74)Nausea, vomiting or diarrhea.21 patients lacked respiratory symptoms of coughing and sputum production, and presented only with GI symptomsSevere/critical: 17/74 with GI symptoms vs 47/577 without GI symptom. In those with GI symptoms, risk factors for severe/critical disease were sputum production, increased lactate dehydrogenase and increased glucose on multivariate analysis.ARDS: 5/74 with GI symptoms vs 12/577 without GI symptomShock: 1/74 with GI symptoms vs 1/577 without GI symptomLiver injury: 13/74 with GI symptoms vs 51/577 without GI symptomMechanical ventilation: 5/74 with GI symptoms vs 12/577 without GI symptom ICU admission: 5/74 with GI symptoms vs 12/577 without GI symptom AST >40: NRGI symptoms M 29.4 (IQR, 29.9–38.6) vs no GI symptoms M 24.4 (IQR, 19.0–32.0)ALT >50: NRGI symptoms M 25.0 (IQR, 15.8–38.5) vs no GI symptoms M 21.5 (IQR, 15.0–32.8)Total bilirubinGI symptoms M 0.6 (IQR, 0.4–0.8) vs no GI symptoms M 0.6 (IQR, 0.4–0.8)